Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an announcement.
CanSino Biologics Inc. has obtained a Good Manufacturing Practice certificate under the Pharmaceutical Inspection Co-Operation Scheme for the manufacturing site of its ACYW135 meningococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine. The certification follows a compliance inspection by Malaysia’s National Pharmaceutical Regulatory Agency and confirms that the company’s manufacturing and quality systems meet PIC/S standards.
The PIC/S GMP recognition is expected to facilitate registration and marketing of the two vaccines in Malaysia and other member jurisdictions that mutually recognize such inspections. This regulatory milestone strengthens CanSino Biologics’ ability to expand its vaccine portfolio in international markets and may enhance its competitive positioning among global vaccine manufacturers, while investors are reminded to remain cautious when trading the company’s shares.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$39.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the research, development and manufacturing of innovative vaccines. The company focuses on conjugate and other advanced vaccines for infectious diseases, targeting both domestic and international markets, including emerging regulatory jurisdictions in Asia and other PIC/S member countries.
Average Trading Volume: 928,733
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.15B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.